Improvement of Cyclophosphamide Activation by CYP2B6 Mutants: From in Silico to ex Vivo
Authors:
- Marina TychopoulosMTMarina Tychopoulos
- Florence BichatFBFlorence Bichat
- Clothilde ZimmermannCZClothilde Zimmermann
- Jean-Pierre FlinoisJFJean-Pierre Flinois
- Monique DiryMDMonique Diry
- Emelie AhlbergEAEmelie Ahlberg
- Marcel DelaforgeMDMarcel Delaforge
- Laurent CorcosLaurent Corcos
- Philippe BeaunePBPhilippe Beaune
- Patrick DansettePDPatrick Dansette
- François AndréFAFrançois André
- 1 April 2008
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 73 (4) , 1122-1133
Abstract
Cyclophosphamide (CPA) is a chemotherapeutic agent that is primarily activated in the liver by cytochrome P4502B6 (CYP2B6) and then transported to the tumor via blood flow. To prevent deleterious secondary effects, P450-based gene-directed enzyme prodrug therapy (GDEPT) consists of expressing CYP2B6 in tumor cells before CPA treatment. Given the relatively low affinity of CYP2B6 for CPA, the aim of our work was to modify CYP2B6 to increase its catalytic efficiency (Vmax/Km) to metabolize CPA into 4′-OH CPA. A molecular model of CYP2B6 was built, and four residues in close contact with the substrate were subjected to mutagenesis. Canine CYP2B11 exhibiting a particularly low Km to CPA, the amino acids exclusively present in the CYP2B11 substrate recognition sequences were substituted in human CYP2B6. All mutants (n = 26) were expressed in Saccharomyces cerevisiae and their enzymatic constants (Km, Vmax) evaluated using CPA as substrate. Five mutants exhibited a 2- to 3-fold higher catalytic efficiency than wild-type CYP2B6. A double mutant, comprising the two most effective mutations, showed a 4-fold increase in Km/Vmax. Molecular dynamic simulations of several mutants were found to be consistent with the observed modifications in catalytic efficiency. Finally, expression of the CYP2B6 114V/477W double mutant, contrary to wt CYP2B6, allowed switching of a resistant human head and neck cancer cell line (A-253) into a sensitive cell line toward CPA. Thus, we were able to obtain a new efficient CYP2B6 mutant able to metabolize CPA, an important step in the GDEPT strategy for human cancer treatment.Keywords
This publication has 39 references indexed in Scilit:
- A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion proteinCancer Gene Therapy, 2005
- Analysis of Differential Substrate Selectivities of CYP2B6 and CYP2E1 by Site-Directed Mutagenesis and Molecular ModelingThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, dockingJournal of Molecular Modeling, 2002
- CYTOCHROME P450-BASED CANCER GENE THERAPY: RECENT ADVANCES AND FUTURE PROSPECTSDrug Metabolism Reviews, 1999
- LINCS: A linear constraint solver for molecular simulationsJournal of Computational Chemistry, 1997
- Expression and Detection of Inducible Nitric Oxide Synthase in Experimental Models of InflammationMethods, 1996
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994
- Comparative Protein Modelling by Satisfaction of Spatial RestraintsJournal of Molecular Biology, 1993
- Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5Gene, 1993
- Molecular dynamics with coupling to an external bathThe Journal of Chemical Physics, 1984